-
Study aim
-
Determining the effect of inulin supplementation on inflammation status, disease severity, and physical performance in patients with rheumatoid arthritis
-
Design
-
The clinical trial with a control group, with parallel groups, double-blind, randomized, phase 3 on 60 patients. A table of random numbers is used for randomization
-
Settings and conduct
-
The current study is a double-blind, randomized, placebo-controlled clinical trial that will be conducted on adult patients with rheumatoid arthritis. Patients will be randomly divided into 2 groups (30 people) to receive inulin supplement or placebo using a random numbers table. The study method will be that the blood tests of the patients, which are routinely requested by the rheumatologist for the patients in each visit, will be checked. Other variables of the study are also examined before and after the intervention (60 days)
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria include age between 30 and 65 years, completion of the consent form before starting the intervention, and not using herbal and medicinal supplements in the last three months, and non-inclusion criteria include pregnancy and breastfeeding, smoking, following a special diet, taking medications. It affects the digestive microbiome, inflammatory bowel diseases, and infectious rheumatoid arthritis, and the use of traditional medicine methods
-
Intervention groups
-
The inulin supplement and placebo will be delivered to the subjects in 10-gram packs, which will be consumed in capsule form along with a specified main meal for 60 days, along with the routine medical treatments prescribed by the doctor
-
Main outcome variables
-
Muscle strength; Morning dryness symptoms; Red blood cell sedimentation rate (ESR); CRP serum level; Disease Activity Score (DAS-28); Visual Analogue Scale (VAS); Health Assessment (HAQ)